Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HMPL-523 in Treatment of Primary Immune Thrombocytopenia (ITP) in Adults(ESLIM-01 Study)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 20 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sovleplenib (Primary)
Indications Idiopathic thrombocytopenic purpura
Focus Registrational; Therapeutic Use
Acronyms ESLIM-01
Sponsors HUTCHMED

Most Recent Events

20 Mar 2025 Last checked against ClinicalTrials.gov: US National Institutes of Health record.
19 Mar 2025 According to a HUTCHMED media release, company expects Complete ESLIM-01 NMPA NDA review around end 2025.
17 Mar 2025 Planned End Date changed from 30 Jun 2025 to 30 May 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com